Last reviewed · How we verify
MG1109
MG1109 is a therapeutic agent in development by Green Cross Corporation currently in phase 3 clinical trials.
At a glance
| Generic name | MG1109 |
|---|---|
| Sponsor | Green Cross Corporation |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Limited publicly available information exists regarding the specific mechanism of action for MG1109. As a phase 3 candidate from Green Cross Corporation, it represents an advanced-stage investigational drug, but detailed mechanistic data have not been widely disclosed in accessible pharmaceutical databases.
Approved indications
Common side effects
Key clinical trials
- Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MG1109 CI brief — competitive landscape report
- MG1109 updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI